Despite guideline recommendations and available evidence, implementation of treatment in
heart failure (HF) is poor. The majority of patients are not prescribed drugs at target doses …

Multiple drug classes have shown incremental benefits in heart failure with reduced ejection
fraction. Most of these trials were designed to achieve specific doses of the investigational …

Objectives This study evaluated the impact of clinical and physiological factors limiting
treatment optimization toward recommended medical therapy in heart failure (HF) …

Novel pharmacologic treatment options reduce mortality and morbidity in a cost‐effective
manner in patients with heart failure (HF). Undisputedly, the effective implementation of …

Background: Guidelines recommend that patients with heart failure with reduced ejection
fraction (HFrEF) have medical therapy titrated to target doses derived from clinical trials, as …

Our therapies for heart failure are prescribed to address at least one of three goals: survival,
quality of life, and prevention of the disease progression that would threaten the first two …

Introduction Patients with symptomatic heart failure (HF) require additive therapies and have
a poor prognosis. However, patient characteristics and clinical outcome between HF …

Medications with proven benefit in patients with heart failure with reduced ejection fraction
are recommended, according to prospective large clinical trials, in the stable patient after …

Aims Previously, guidelines recommended initiating therapy in patients with heart failure
and reduced ejection fraction (HFrEF) in a sequence that follows the chronological order in …

Heart failure (HF) is a syndrome characterized by high mortality, frequent hospitalization,
reduced quality of life, and a complex therapeutic regimen. Knowledge about HF is …